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Meier-Gorlin syndrome
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Andrew P. Jackson5 and Ernie MHF Bongers1*
Abstract
Meier-Gorlin syndrome (MGS) is a rare autosomal recessive primordial dwarfism disorder, characterized by microtia,
patellar applasia/hypoplasia, and a proportionate short stature. Associated clinical features encompass feeding
problems, congenital pulmonary emphysema, mammary hypoplasia in females and urogenital anomalies, such as
cryptorchidism and hypoplastic labia minora and majora. Typical facial characteristics during childhood comprise a
small mouth with full lips and micro-retrognathia. During ageing, a narrow, convex nose becomes more prominent.
The diagnosis MGS should be considered in patients with at least two of the three features of the clinical triad of
microtia, patellar anomalies, and pre- and postnatal growth retardation. In patients with short stature and/or
microtia, the patellae should be assessed with care by ultrasonography before age 6 or radiography thereafter.
Mutations in one of five genes (ORC1, ORC4, ORC6, CDT1, and CDC6) of the pre-replication complex, involved in
DNA-replication, are detected in approximately 67-78 % of patients with MGS. Patients with ORC1 and ORC4
mutations appear to have the most severe short stature and microcephaly.
Management should be directed towards in-depth investigation, treatment and prevention of associated problems,
such as growth retardation, feeding problems, hearing loss, luxating patellae, knee pain, gonarthrosis, and possible
pulmonary complications due to congenital pulmonary emphysema with or without broncho- or laryngomalacia.
Growth hormone treatment is ineffective in most patients with MGS, but may be effective in patients in whom
growth continues to decrease after the first year of life (usually growth velocity normalizes after the first year) and
with low levels of IGF1. At present, few data is available about reproduction of females with MGS, but the risk of
premature labor might be increased.
Here, we propose experience-based guidelines for the regular care and treatment of MGS patients.
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Review
In this review, we outline the clinical symptoms of MGS
and propose experience-based guidelines for care and
treatment of MGS patients. The reported percentages of
clinical symptoms are calculated from the frequency of
these symptoms in the 38 patients with bi-allelic muta-
tions in one of the five causative pre-replication complex
genes (ORC1, ORC4, ORC6, CDT1, and CDC6) described
in literature [1–5]. Clinical symptoms that may affect
management and that are present only in patients with
clinically diagnosed MGS (in whom the molecular defect
is unknown) are mentioned as well.
Disease name and synonyms
Meier-Gorlin syndrome (MGS; MIM#224690, ORPHA
2554).
Ear patella short stature syndrome (EPS).
Definition
Meier-Gorlin syndrome (MGS) is characterized by the
triad of microtia, absent or small patellae and short
stature. At least two of these three clinical features are
present in 97 % (32/33) of patients with MGS, the
combination of patellar a-/hypoplasia and microtia being
the most prevalent. Microtia, however, can be mild. One
patient was described with short stature, but without
microtia or patellar anomalies, indicating that the clin-
ical phenotype might be more variable than previously
suspected [3, 4].
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Epidemiology
Until now, 67 patients with MGS have been described
since the first reported patients by Meier in 1959 and
Gorlin in 1975 (30 males; 36 females; 1 of unknown sex;
age range 0.3-55 years) [1–22]. The underlying molecu-
lar defect is known in 38 of these patients [1–5].
The exact prevalence of MGS has not been deter-
mined, but is estimated to be less than 1-9/1,000,000
based on the number of cases described in literature.
However, this might be an underestimation, due to
underreporting and missed diagnoses.
Clinical description
Patients with MGS present with a recognizable phenotype.
The classical triad of clinical features comprises microtia,
patellar aplasia or hypoplasia, and pre- and postnatal
growth retardation.
Microtia is present in almost all patients with MGS
(34/36; 94 %). Severity ranges from mild to severe
microtia, where the ears appear underdeveloped and
low-set. Narrow ear canals and conductive hearing loss
may accompany microtia.
Patellar anomalies are among the most frequent findings
in MGS (31/33; 94 %). In most patients, patellae are
absent, but they may be hypoplastic.
Prenatal growth is delayed in the majority of patients
with MGS. Intra uterine growth retardation (IUGR) was
present in 97 % (35/36), with a mean birth weight of −3.8
SD (range < −6.5 SD to −0.3 SD), five infants were born
prematurely (5/30; 17 %; terms ranging from 28 to
36 weeks of gestation) [2–4]. In three cases, the pregnancy
was terminated because of severe IUGR, in combination
with congenital anomalies [5].
We studied growth extensively in our cohort of 45 MGS
patients (35 patients with a known and 10 with an un-
known molecular defect) [23]. Postnatal growth was de-
layed during the first year of life. Growth velocity was
almost normal thereafter, with patients growing parallel to
the normal growth charts without significant catch up
growth. In this cohort, height varied considerably between
MGS patients and ranged from −9.6 SD to −0.4 SD. The
average adult height in the MGS patients with a known
underlying molecular defect was −5.5 SD (5 patients).
Microcephaly (head circumference < −3SD) was present
in 43 % (13/30) of patients, with a head-circumference
ranging from −9.8 SD to +1.7 SD. Height differed signifi-
cantly between the gene mutated, ethnic background and
gender. Patients with mutations in ORC1 and ORC4 had a
significantly shorter stature (a difference of 4,7 SD and 3.1
SD, respectively) and smaller head circumference (a differ-
ence of 5.0 SD and 1.6 SD, respectively), than patients
with mutations in ORC6, CDT1, or CDC6 [4, 23].
Growth hormone therapy was unsuccessful in MGS
patients with a known molecular defect. However,
growth hormone therapy was successful in two patients
with a clinical diagnosis of MGS, whose growth velocity
continued to be low after the first year and who had low
levels of IGF1 (−3.3 SD and −4.6 SD) [23].
All postpubertal females (10/10; 100 %) had mammary
hypoplasia. Transvaginal ultrasound investigations were
performed in five adult females (clinically diagnosed with
MGS). A small uterus was reported in three of them and
polycystic ovaries were reported in two of these five
females [23].
Axillary hair is often sparse or absent, while pubic hair
generally is normal in both males and females.
Furthermore, patients with MGS have a recognizable
facial phenotype with microstomia, full lips and retro-/
micrognathia at young age (Fig. 1). The nose can be narrow
and convex with a high nasal bridge. These characteristics
of the nose become more prominent with age.
Intellect is normal in the majority of patients with MGS
(30/31; 97 %), although delayed motor development and/
or speech development without intellectual disability (ID)
were present in 19 % (6/32) and 16 % (5/32) of patients,
respectively. A mild ID was present in one patient (3 %).
Respiratory tract anomalies are relatively frequent. Con-
genital pulmonary emphysema was reported in 43 % (12/
28) of patients with MGS. Congenital pulmonary emphy-
sema is usually detected in the neonatal period or early in
childhood(10/12; 83 %), but can be diagnosed late in
childhood. Bronchomalacia, laryngomalacia and/or tra-
cheomalacia are reported in 42 % (10/24) of subjects.
Recurrent respiratory tract infections occur often during
childhood, but disappear thereafter.
Congenital cardiac anomalies appear to be rare: they
have been described in two patients (2/30; 7 %: one ven-
tricular septal defect, one patent ductus arteriosus).
Feeding problems are seen in approximately 80 %
(26/32) of patients with MGS during infancy and young
childhood. Problems range from a small appetite (which
may correlate with the short stature of infants), to gastro-
esophageal reflux with administration of tube feeding or
gastrostomy interventions in 35 % (11;31).
Anomalies of the urogenital tract are frequently reported,
especially cryptorchidism in males (9/14; 64 %) and hypo-
plastic labiae in females (5/21; 24 %).
A delayed bone age and genu recurvatum are often
seen in patients with MGS. Joint contractures, including
club feet, were present in 23 % (7/30) of patients.
Not much is known about the reproduction of patients
with MGS. Recently, a previously described woman clinic-
ally diagnosed with MGS gave birth prematurely twice
after 17 and 18 weeks of gestation, respectively [23].
Aetiology
MGS is an autosomal recessive disorder. Mutations in
five genes of the pre-replication complex (ORC1, ORC4,
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ORC6, CDT1 and CDC6), were detected in patients with
MGS. Mutation detection rate was approximately 78 %
in a cohort of 45 patients with MGS [4]. The pre-
replication complex assembles on genomic DNA at
origins of replication.
The exact underlying mechanism for the clinical fea-
tures of MGS remains to be elucidated. The impaired
function of the pre-replication complex (PRC) is pre-
sumed to reduce the G1 phase of DNA replication and to
limit the available time for origin licensing. This limitation
is hypothesized to become rate-limiting, thereby impeding
cellular proliferation. This would result in a reduction of
the total cell number and thereby diminish overall growth
[24, 25]. Another possible mechanism affecting cell cycle
progression was identified in ORC1 depleted cells, where
a defect in the rate of formation of primary cilia was dem-
onstrated to influence cell cycle progression [26]. Alterna-
tively, the ORC1 subunit of the PRC contains distinctive
domains that regulate centriole and centrosome copy
number. It is suggested that mutations in these domains
alter centrosome duplication and thereby contribute to
the growth retardation and microcephaly in MGS [27].
Mutations in ORC1 and ORC4 appear to cause a more
severe short stature and microcephaly than mutations in
other genes. Furthermore, compound heterozygous mis-
sense- and loss of function mutations appear to have a
more severe effect on the phenotype than homozygous or
compound heterozygous missense mutations [4]. No
patients are known with homozygous or compound
heterozygous loss of function mutations, suggesting
that these mutations cause a lethal phenotype. No add-
itional genotype-phenotype correlations were recognized.
Diagnostic methods
The clinical diagnosis of MGS can be established in
the presence of microtia, patellar aplasia or hypopla-
sia, and proportionate short stature. However, about
18 % (6/33) of patients show only two out of three
cardinal features, and one patient was described with
short stature only.
Fig. 1 Facial features of Meier-Gorlin syndrome. Patient A is a girl aged 7 years and 9 months with two mutations in ORC4. Patient B is a 14 year
old girl, who carries one mutation in ORC1. Both show the characteristic facial features of MGS, including microtia, a prominent nose with a
convex nasal profile, a small mouth with full lips, and retro-/micrognathia
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The diagnosis MGS should be considered in patients
with short stature or microtia, and the presence of these
features necessitates comprehensive examination of the
patellae. In infants, ultrasound investigations are advised,
since patellae are radiolucent in the first 5–6 years of life
and will not be visible by conventional radiography.
Furthermore, the characteristic facial features and
mammary hypoplasia are specific findings for MGS and
will assist in diagnosing MGS.
In a patient clinically suspected to have MGS, the diag-
nosis can be confirmed by detecting compound heterozy-
gous or homozygous mutations in one of the five pre-
replication complex genes (ORC1, ORC4, ORC6, CDT1,
and CDC6). Mutations were detected in approximately
78 % of patients clinically suspect for MGS [4]. In patients
with a severe short stature and/or microcephaly, starting
with the analysis of ORC1 and ORC4 should be consid-
ered, since mutations in these two genes are associated
with a significantly shorter stature and smaller head cir-
cumference than mutations in the other genes [4, 23].
Differential diagnosis
The association of microtia, patellar anomalies and short
stature as such has not been described in other syndromes.
MGS is a part of the primordial dwarfism spectrum.
These disorders are characterized by microcephaly and
prenatal short stature. Other primordial dwarfism
disorders include Seckel syndrome and Microcephalic
Osteodysplastic Primordial Dwarfism (MOPD) type I, II
and III. However, even though these syndromes show
considerable overlap with MGS, they are clinically distinct
disorders. In Seckel syndrome, short stature is proportion-
ate, as in MGS. However, height and head circumference
are generally much smaller in Seckel syndrome than in
MGS (average −7.1SD and −8.7SD, respectively [28]), the
facial appearance differs from MGS, and patients generally
have ID. These patients can have patellar anomalies and
microtia, but these findings are not frequently present,
contrary to MGS, where they are mandatory features.
Patients with MOPD type 1 and 2 have a dispropor-
tionate short stature, and a skeletal dysplasia, clearly
distinguishing these disorder from MGS. MOPD type 3 is
rare and it is suggested this is the same disorder as
MOPD type 1. Stature in patients with MOPD type 3 was
proportionate, though.
Patellar anomalies and short stature are cardinal
features of RAPADILINO and genitopatellar syndrome.
However, these syndromes differ from MGS in the lack
of microtia (both), the presence of radial ray defects
(RAPADILINO), and developmental delay and agenesis
of the corpus callosum (genitopatellar syndrome).
If patellar anomalies are present, and microtia and
short stature are absent, nail patella syndrome should be
considered. In nail patella syndrome, familial patellar
a-/hypoplasia is almost always accompanied by nail dys-
plasia, including the pathognomic tri-angular lunulae.
An overview of other syndromes with patellar anomalies,
such as small patella syndrome, patella aplasia-hypoplasia,
and trisomy 8 mosaicism is provided by Bongers et al [29].
In patients with microtia, other diagnoses to contemplate
are branchio otorenal syndrome, Townes-Brocks syndrome,
Treacher-Collins syndrome, Nager syndrome, Miller
syndrome, and CHARGE association.
Genetic counselling
MGS is an autosomal recessive disorder. The recurrence
risk for a couple with an affected child is 25 %. Parents are
obligate heterozygotes. Heterozygotes are asymptomatic.
In literature, three patients with a classic MGS phenotype
and mono-allelic mutations (one in ORC1, two in CDT1)
were described. However, their healthy fathers carried the
same mutation. Therefore, it is expected that these
patients either carry a second mutation in ORC1 or CDT1
that cannot be detected with the current molecular tech-
niques, or that their symptoms were caused by a different
molecular defect.
To our knowledge, so far, no patients with MGS have
had any children. However, future reports are expected.
Offspring of a patient with MGS are obligate heterozy-
gotes. The risk of having an affected child with MGS is
low (<1 %), since carrier frequencies and thus the risk of a
partner being a carrier are low.
Antenatal diagnosis
When the underlying molecular defect is known, pre-
natal diagnosis by chorionic villus sampling or amnio-
centesis is possible. If no causative gene defects are
identified, prenatal ultrasound investigations at 18–20
weeks of gestation may contribute to the recognition of
MGS. However, it is unknown whether overall growth is
already delayed at this term. Microtia and congenital
pulmonary emphysema can be seen and certain facial
features, such as micrognathia may be detected. None-
theless, because of the variable expression of the dis-
order and the lack of structural congenital anomalies,
ultrasound abnormalities may be absent, or mild and
difficult to interpret. The ethical issues of prenatal diag-
nosis and possible termination of a pregnancy for a dis-
order with a variable expression, and a relatively low
chance of life-threatening complications or intellectual
disability, should be discussed.
Management
Especially during childhood, multidisciplinary care is
needed.
Here, we propose guidelines for regular care and
treatment, based on clinical experience. An overview of
the proposed guidelines for diagnostic evaluation and
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management of patients with MGS is presented in
Additional file 1: Table S1.
Ears
Microtia can be associated with narrow ear canals and
conductive hearing loss. Therefore, at the time of diagno-
sis, a patient suspected to have MGS should be examined
by an ear-nose-throat specialist. Afterwards, examinations
are indicated when hearing loss appears to be present.
Patellae
Patellar aplasia or hypoplasia may lead to instability of the
knee joint, pain and early gonarthrosis. A multidisciplinary
approach, including examination by an orthopedic
surgeon and rehabilitation physician is advised. Special
shoes and advise about strength enhancing exercises and
sports, may be provided, especially since patients with
MGS often have hypermobile joints and are more prone
to develop pes planus.
Growth and growth hormone treatment
Growth hormone treatment was effective in only four
patients, one with ORC4 mutations, one with CDC6
mutations and two without mutations [4, 23]. In one
patient with CDC6 mutations, height improved from −5
to −3 SD during the first 4 years. In two patients without
mutations, height improved from −6.8 SD to −3.0 SD and
from −5.7 SD tot −3.7 SD.
In a child with MGS, endocrinological evaluation
(IGF1 and stimulated growth hormone measurements)
is advised. Growth hormone treatment should be con-
sidered in a patient with low IGF1 levels and further
delay of growth after the first year.
Feeding problems
Feeding problems can be severe, necessitating tube feed-
ing and a gastrostomy to optimize nutrition. Gastroesoph-
ageal reflux as a cause should be considered.
Congenital pulmonary emphysema
Surgical resection can be performed when respiratory
distress is life-threatening or debilitating. In older patients
with MGS and congenital pulmonary emphysema treat-
ment with selective Beta2-antagonists can be considered.
Congenital cardiac anomalies
Since 7 % of the reported MGS patients had a congenital
cardiac anomaly, we advise cardiac screening (physical
examination, ECG and ultrasound investigations) at the
time of diagnosis.
Mammary hypoplasia
Treatment of mammary hypoplasia with exogenous
estrogen can be debated in females with MGS. Estrogen
therapy was reported to be successful in two females
with MGS. In a third female, minor effects were re-
ported. In two other females, no effect was seen [4, 23].
Breast augmentation surgery can be considered.
Reproduction
Males born with cryptorchidism may have fertility prob-
lems. One female with MGS had two consecutive
miscarriages. Her uterus was described to be small. No
information about other pregnancies is available, but
preconceptional gynaecologic examinations should be
considered and possible preterm labor should be a point
of attention in obstetric care of females with MGS, espe-
cially since gynecologic evaluation in four other females
with MGS revealed a small uterus and polycystic ovaries
in two of them [23].
Prognosis
Life span is expected to be normal for most individuals
with MGS. Osteoarthritis of the knees, secondary to pa-
tellar anomalies, may occur at a younger age than usual.
Life threatening complications that may accompany
MGS are severe congenital pulmonary emphysema and
cortical malformations. When severe congenital anomalies
and/or severe respiratory problems are absent, however,
there is no reason to expect an abnormal life span.
Four reported patients with MGS were deceased
(11 %), and three pregnancies were terminated because
of ultrasound abnormalities, including severe IUGR
(8 %) [3–5, 16].
One patient (with ORC1 mutations) passed away
after 3,5 months. He had a severe cortical dysplasia,
pachygyria and ventricular enlargement, cranial suture
stenosis, congenital emphysema of the lung, and his pan-
creatic tail was absent. His brother died in utero after
17 weeks of gestation. Both patients exhibited microtia
and a severe growth retardation. A third patient (with
CDT1 mutations) deceased after a sudden cardiac arrest.
He had congenital pulmonary emphysema for which he
required surgery. His sister passed away after 3 months.
She had severe respiratory problems due to a tracheo-
bronchomalacia with progressive pulmonary emphysema.
Unresolved questions
The long-term risks of congenital pulmonary emphysema
in patients with MGS need to be evaluated through long-
term follow-up. Furthermore, future reports about
reproduction in patients with MGS have to be awaited to
assess the exact reproductive risks.
Approximately 22 % of patients with a classical clinical
phenotype of MGS lacked mutations in one of the five
known genes of the pre-replication complex [4]. These
patients might have mutations in one of the five known
genes we are unable to detect with current sequencing
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techniques, or their symptoms may be caused by muta-
tions in other genes of the pre-replication complex, or in
pathways connected to this complex.
It is currently unknown why patients with ORC1 and
ORC4 mutations appear to have shorter stature and
smaller head circumference compared to patients with
mutations in other genes. Further understanding of the
role of the different genes of the pre-replication complex
during growth and development might contribute to
gain insight in these differences.
Conclusions
Here, we provide an overview of the clinical features of
Meier-Gorlin syndrome and guidelines for management
and treatment of associated problems in this rare disorder.
MGS is an autosomal recessive primordial dwarfism dis-
order characterized by microtia, patellar a-/hypoplasia and
short stature and often accompanied by feeding problems,
respiratory problems, mammary hypoplasia and urogenital
anomalies.
Multidisciplinary care, directed towards diagnosis and
treatment of ear anomalies and/or hearing loss, patellar
anomalies, feeding problems, respiratory problems, and
possible reproductive issues, is necessary to assure optimal
medical care. Endocrinologic testing should be routinely
performed in all children with MGS, although growth
hormone treatment is not beneficial in most patients with
MGS.
Molecular analysis of the five known genes for MGS
(ORC1, ORC4, ORC6, CDT1, and CDC6) is important in
genetic counseling. A molecular diagnosis assists in deter-
mining the exact recurrence risk and enables future repro-
ductive options, such as preimplantation genetic diagnosis
and invasive diagnostic testing during pregnancy.
Since a molecular diagnosis cannot be established in
20-35 % of patients with MGS, further studies are necessary
to identify the underlying genetic defects in these patients.
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